Life Science REIT is to apply for a premium listing on the main market of the London Stock Exchange.
In a statement this morning, the REIT, which more than doubled its value to £413m in its first six months since its AIM IPO, said its migration was already “well progressed”.
It added that it would publish its prospectus in the next few weeks, with admission expected by early December.
Chair Claire Boyle said: “We are pleased to propose this important milestone for the company outlined at the time of our IPO completed in November 2021. Comfortably within the 12 months since that date, the company has secured a substantial and diverse portfolio of quality life science properties in Oxford, Cambridge and London which the board believe has significant growth potential.”
She added: “We look forward to joining the main market with the anticipated benefits of a potentially larger pool of capital to further improve liquidity, enhance the company profile and consideration for eligibility to be included in a broader range of equity indices.”
To send feedback, e-mail piers.wehner@eg.co.uk or tweet @PiersWehner or @EGPropertyNews
